JP5705985B2 - 医薬品合成用中間体化合物の製造方法 - Google Patents
医薬品合成用中間体化合物の製造方法 Download PDFInfo
- Publication number
- JP5705985B2 JP5705985B2 JP2013527003A JP2013527003A JP5705985B2 JP 5705985 B2 JP5705985 B2 JP 5705985B2 JP 2013527003 A JP2013527003 A JP 2013527003A JP 2013527003 A JP2013527003 A JP 2013527003A JP 5705985 B2 JP5705985 B2 JP 5705985B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- group
- reaction
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 176
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- 230000015572 biosynthetic process Effects 0.000 title description 23
- 238000003786 synthesis reaction Methods 0.000 title description 23
- 238000000034 method Methods 0.000 claims description 45
- -1 t- butyl Chemical group 0.000 claims description 42
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 31
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 claims description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
- 125000004185 ester group Chemical group 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 9
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 9
- VFPWGZNNRSQPBT-UHFFFAOYSA-N 2-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1Br VFPWGZNNRSQPBT-UHFFFAOYSA-N 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 238000005984 hydrogenation reaction Methods 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 claims description 8
- 125000003368 amide group Chemical group 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 7
- DYUWTXWIYMHBQS-UHFFFAOYSA-N n-prop-2-enylprop-2-en-1-amine Chemical compound C=CCNCC=C DYUWTXWIYMHBQS-UHFFFAOYSA-N 0.000 claims description 6
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 238000006264 debenzylation reaction Methods 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 2
- 125000006242 amine protecting group Chemical group 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- LCIYFINKFGDAHD-UHFFFAOYSA-N azepane;3-nitrobenzoic acid Chemical compound C1CCCNCC1.OC(=O)C1=CC=CC([N+]([O-])=O)=C1 LCIYFINKFGDAHD-UHFFFAOYSA-N 0.000 claims description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 claims 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 72
- 239000000243 solution Substances 0.000 description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
- 239000012044 organic layer Substances 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 7
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000005270 trialkylamine group Chemical group 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000013076 target substance Substances 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- STXLDWKKRMDGOR-QMMMGPOBSA-N C(C)(C)(C)NC(C[C@H](NC(=O)OC(C)(C)C)C(=O)N)=O Chemical compound C(C)(C)(C)NC(C[C@H](NC(=O)OC(C)(C)C)C(=O)N)=O STXLDWKKRMDGOR-QMMMGPOBSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- PHJDCONJXLIIPW-QMMMGPOBSA-N (2s)-4-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C PHJDCONJXLIIPW-QMMMGPOBSA-N 0.000 description 1
- SJUBMDQYZUKITC-ZETCQYMHSA-N (3s)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)C)NC(=O)OC(C)(C)C SJUBMDQYZUKITC-ZETCQYMHSA-N 0.000 description 1
- IRFCLLARAUQTNK-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl chloride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(Cl)(=O)=O IRFCLLARAUQTNK-UHFFFAOYSA-N 0.000 description 1
- QKIHLPFZYGFMDK-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4-nonafluorobutylsulfonyl 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F QKIHLPFZYGFMDK-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VVSASNKOFCZVES-UHFFFAOYSA-N 1,3-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CN1C(=O)CC(=O)N(C)C1=O VVSASNKOFCZVES-UHFFFAOYSA-N 0.000 description 1
- VCHFJVJNAVWBHG-UHFFFAOYSA-N 2-amino-2-[(2-methylpropan-2-yl)oxycarbonyl]butanoic acid Chemical compound CCC(N)(C(O)=O)C(=O)OC(C)(C)C VCHFJVJNAVWBHG-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NYFSYIFADKELCR-UHFFFAOYSA-N 4-(5,5-difluoro-2-oxopiperidin-1-yl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)CN1CC(F)(F)CCC1=O NYFSYIFADKELCR-UHFFFAOYSA-N 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- KAJBMCZQVSQJDE-YFKPBYRVSA-N Nalpha-(tert-butoxycarbonyl)-l-aspartic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(O)=O KAJBMCZQVSQJDE-YFKPBYRVSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- PXURRFCLQDNZOY-UHFFFAOYSA-L carbon monoxide;dichlororuthenium;triphenylphosphane Chemical compound [Cl-].[Cl-].[Ru+2].[O+]#[C-].[O+]#[C-].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 PXURRFCLQDNZOY-UHFFFAOYSA-L 0.000 description 1
- 239000007809 chemical reaction catalyst Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- GGVOVPORYPQPCE-UHFFFAOYSA-M chloronickel Chemical compound [Ni]Cl GGVOVPORYPQPCE-UHFFFAOYSA-M 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- YVPKMLFMDHSTKJ-UHFFFAOYSA-N diethyl 2,2-difluoropentanedioate Chemical compound CCOC(=O)CCC(F)(F)C(=O)OCC YVPKMLFMDHSTKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- IAURJAZOQMEKRP-UHFFFAOYSA-N ethyl 4,4-difluoro-5-hydroxypentanoate Chemical compound CCOC(=O)CCC(F)(F)CO IAURJAZOQMEKRP-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- BITKFESLEDFJMG-QMMMGPOBSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxopentanoate Chemical compound COC(=O)[C@H](CC(C)=O)NC(=O)OC(C)(C)C BITKFESLEDFJMG-QMMMGPOBSA-N 0.000 description 1
- GJFJDKALAUIPSO-UHFFFAOYSA-N methyl 5-amino-4,4-difluoropentanoate;hydrochloride Chemical compound Cl.COC(=O)CCC(F)(F)CN GJFJDKALAUIPSO-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- JGTNAGYHADQMCM-UHFFFAOYSA-N perfluorobutanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JGTNAGYHADQMCM-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
R2は、水素、置換又は非置換のC1−C10アルキル,置換又は非置換のC3−C10シクロアルキル、置換又は非置換のC4−C8アリール及び置換又は非置換のC3−C7ヘテロアリールよりなる群から選ばれ:そして
R3、R4、R5及びR6は、独立して、水素、ハロゲン、又は置換又は非置換のC1−C4アルキルである。
P1はアミン保護基であり、好ましくは、P1はBoc(ブチルオキシカルボニル)、Cbz(ベンジルオキシカルボニル)又はFmoc(9−フルオレニルメチルオキシカルボニル)であり、より好ましくは、Bocである。
本発明による式(2)の化合物を製造する方法は、式(4)の化合物を式(5)の化合物と反応させることを特徴とし、さらに当該2つの化合物を反応させた後、式(4)の化合物由来のカルボン酸保護基を除去する工程を含む。
P2及びP3は、独立して、ベンジル基、メチル基、エチル基、i−プロピル基又はt−ブチル基であり;
G1は、酸素と共に、優れた離脱基として機能し、
G1Oは、トリフレート(トリフルオロメタンスルホン酸)、メシレート、トシレート、ベシレート又はノナフレート(ノナフルオロブタンスルホン酸)であり、好ましくはトリフレート又はノナフレートである。
(a)式(4)の化合物と式(5)の化合物に塩基を加えて、カップリング反応を行う工程;
(b)酸を加えて、環化反応を行って、式(2a)化合物を得る工程;及び
(c)得られた式(2a)の化合物を加水分解し、カルボン酸保護基を除去して、式(2)の化合物を得る工程。
bは、AcOHなどの酸と、CH2Cl2などの有機溶媒であり;
cは保護基によって異なるが、具体的には、P1がBoc、P2がt−ブチル基である場合、(1)H2SO4などの強酸とCH2Cl2、aq.NaOH、Boc2O、及び(2)NaOH、EtOH、H2O、還流の条件から選ばれ、又はP1がBoc、P2がベンジル基、メチル基、エチル基及びi−プロピル基である場合、上記の条件(2)に特定された塩基を用いる加水分解条件である。
R3、R4、R5、R6、P1、P2、P3及びG1は上で定義された通りである。
式(2)の化合物を製造するために用いられる出発物質の一つとしての式(5)の化合物は、公知化合物である式(7)の化合物から製造でき、これは、特許文献1に開示されるように、式(6)の化合物から下記反応式4に示された方法で得ることができる。
(a)式(7)の化合物を還元して1級アルコール化合物を得る工程;及び
(b)前記で得られたアルコール化合物と式(2)の化合物のG1O部分に対応するG1化合物とを反応させて、式(5)の化合物を得る工程を含む。この方法は、下記反応式5として表される。
Xは、Br、F又はClなどのハロゲンであり;
P4は、ベンジル基、メチル基、エチル基、i−プロピル基又はt−ブチル基であり;
R3、R4、R5、R6及びP3は上で定義された通りである。
bはトリフロオロメタンスルホン酸無水物(Tf2O)、トリフルオロメタンスルホニルクロリド(TfCl)、メタンスルホニルクロリド(MsCl)、トルエンスルホニルクロリド(TsCl)、ブロモベンゼンスルホニルクロリド(BsCl)、(CF3(CF2)3SO2)F又は(CF3(CF2)3SO2)2O、ピリジン又はトリアルキルアミン、及びCH2Cl2であり;
R3、R4、R5、R6、P3、P4及びG1は上で定義された通りである。
一方、式(2)の化合物を製造するために用いられる出発物質の残りの一つとしての式(4)の化合物は下記方法のうちの何れかにより製造される。
(a)式(8)の化合物のカルボン酸基にP2基を導入し、エステル基に変換して、式(9)の化合物を得る工程、
(b)式(9)の化合物に存在するエステル基P5を選択的に還元して、式(10)の化合物を得る工程、
(c)式(10)の化合物にG2O離脱基を導入して、式(11)の化合物を得る工程、
(d)式(11)の化合物をアジド化合物と反応させて、式(12)の化合物を得る工程、及び
(e)式(12)の化合物を水素化して、式(4)の化合物を得る工程を含む。
bは、NaBH4、及びMeOH又はEtOHであり;
cは、Tf2O、MsCl、TsCl、(CF3(CF2)3SO2)F、又は(CF3(CF2)3SO2)2Oなど、ピリジン又はトリアルキルアミン、CH2Cl2であり;
dは、NaN3、DMF又はNMP又はDMAc又はDMAc/EtOAc又はDMAc/H2O又はDMAc/MeOH、加熱であり;
eは、条件(1)H2、Pd/C、MeOH又はEtOH、(2)NaBH4、Pd/C、MeOH、(3)PPh3、H2O、THF、及び(4)トリアルキルホスフィン又はトリアルキルホスファイト、H2O、THFから選ばれ;
P5は、メチル基、エチル基、i−プロピル基又はt−ブチル基であり;
G2は酸素と一緒になって、トリフレート、メシレート、トシレート、ベシレート、ノナフレートなどを含む優れた離脱基であり;
P1、P2は上で定義された通りである。
(a)式(13)のカルボン酸化合物を活性化エステルに変換した後、これを2級アミン化合物と反応させて、式(14)のアミド化合物を得る工程、
(b)式(14)化合物のアミド基を還元して、式(15)の3級アミン化合物を得る工程、及び
(c)式(15)の3級アミン化合物に脱ベンジル化反応を行って、式(4)の化合物を得る工程を含む。この方法は、下記反応式7として表される。
bは、条件(1)反応触媒としてOs(CO)12、Ru(CO)12、RuCl2(CO)2(PPh3)2又はRuH2(CO)2(PPh3)2、Et3SiH、トルエン、還流、(2)反応触媒として、RuH(CO)(PPh3)3、Ru3(CO)12又はRuCl(PPh3)3、Ph2SiH2、PMHS(ポリジメチルシロキサン)、THF又は2−MeTHF、1,4−ジオキサン、エチルエーテル、トルエン、(3)9−BBN(9−ボラビシクロ[3,3,1]ノナン)、THF、還流、及び(4)BH3.DMS又はBH3.THF、トルエン、加熱;から選ばれ;
P6はモノベンジルアミン又はジベンジルアミン又はモノアリルアミン又はジアリルアミンであり、
P1及びP2は上で定義された通りである。
(a)式(13)のカルボン酸化合物を活性化エステルに変換した後、窒素源化合物と反応させて、式(16)のアミド化合物を得る工程、
(b)式16のアミド化合物のアミド基を還元して、式(17)のニトリル化合物を得る工程、及び
(c)式(17)のニトリル化合物に水素化反応を行って、式(4)の化合物を得る工程を含む。この方法は、下記反応式8として表される。
bは、条件(1)(CF3CO)2O、Et3N、及び(2)シアヌル酸、DMFから選ばれ;
cは、条件(1)Pd/C、H2、AcOH、45psi、(2)NiCl.6H2O、NaBH4、(3)CF3CO2H、NaBH4、(4)PtO2、H2、AcOH、(5)PtO2、H2、EtOH、CHCl3、(6)Pd(OH)2、H2、MeOH:AcOH(1:1)又はAcOH:トルエン(1:1)、及び(7)Pd(OH)2、H2、AcOHから選ばれ;
P1、P2は上で定義された通りである。
1.26(t,J=7.2Hz,3H),1.37(t,J=7.2Hz,3H),
2.37−2.49(m,2H),2.55(t,J=7.2Hz,2H),
4.16(q,J=7.2Hz,2H),4.29(q,J=7.2Hz,2H).
1.23(t,J=7.2Hz,3H),2.15−2.29(m,2H),
2.49(t,J=7.2Hz,2H),3.69(t,J=12.0Hz,2H),
4.12(q,J=4.0Hz,2H).
1.27(t,J=7.2Hz,3H),2.29−2.39(m,2H),
2.59(t,J=7.6Hz,2H),4.18(q,J=7.2Hz,2H),
4.55(t,J=11.6Hz,2H).
1.26(t,3H,J=7.3Hz),2.30−2.36(m,2H),
2.58(t,2H,J=7.4Hz),4.16(q,2H,J=7.3Hz),
4.57(t,2H,J=11Hz).
前記製造例2で得られた化合物(500.0g)をジクロロメタン(1000.0mL)に溶かした溶液にトリエチルアミン(389.0g)を加え、次いで混合物を0℃に冷却した。冷却完了後、ペルフルオロブタンスルホニルクロリド(948.8g)をゆっくり滴加した。反応溶液を室温で3時間撹拌し、反応液を減圧蒸留して、メチルt−ブチルエーテル(MTBE、3000.0mL)に溶かした後、水で3回洗浄した。このようにして得られた有機層を硫酸マグネシウムで脱水し、セライトろ過後、減圧蒸留して、表題化合物(960.0g)を得た。
1.45(s,9H),1.47(s,9H),
2.71(dd,J=4.8,16.4Hz,1H),
2.88(dd,J=4.4,16.4Hz,1H),3.75(s,3H),
4.53(m,1H),5.44(br d,J=8.0Hz,1H).
1.44(s,9H),1.45(s,9H),2.48−2.57(m,2H),
3.69(d,J=4.9Hz,1H),3.97(m,1H),
5.22(bs,1H).
1.44(s,9H),1.46(s,9H),
2.62(d,J=6.0Hz,2H),3.04(s,3H),
4.21(m,1H),4.30(d,J=5.2Hz,2H),
5.16(br d,J=7.2Hz,1H).
1.47(s,9H),1.49(s,9H),
2.49(d,J=6.0Hz,2H),3.44−3.55(m,2H),
4.09(br s,1H),5.14(br s,1H).
1.44(s,9H),1.45(s,9H),
2.45(d,J=6.1Hz,2H),2.77(d,J=5.5Hz,2H),
3.87(br s,1H),5.22(br s,1H).
7.32(m,5H),7.20(m,5H),5.39(d,J=7.2Hz,1H), 5.30(m,1H),4.87−4.77(m,2H),
4.48−4.39(m,2H),
2.72(dd,J=15.8Hz,J=8.0Hz,1H),
2.56(dd,J=15.8Hz,J=6.4Hz,1H),
1.43(s,9H),1.37(s,9H).
Mass(ESI,m/z):491(M+Na),469(M+H),
413(M−55).
5.78(m,2H),5.30(m,1H),5.23−5.11(m,1H),
5.30(m,1H),4.93(m,1H),4.11−3.84(m,4H),
2.68(dd,J=15.8Hz,J=8.0Hz,1H),
2.51(dd,J=15.8Hz,J=8.0Hz,1H),
1.44(s,9H),1.42(s,9H).
Mass(ESI,m/z):391(M+Na),369(M+H),
313(M−55).
7.31−7.20(m,10H),5.12(bs,1H),
3.90(bs,1H),3.63(d,J=12.0Hz,2H),
3.48(d,J=12.0Hz,2H),3.24(m,1H),
3.16(bs,1H),2.42(m,2H),1.81(m,1H),
1.59(m,9H),1.46(s,9H),1.06(s,9H).
Mass(ESI,m/z):455(M+H),441(M−13).
1.44(s,9H),1.45(s,9H),
2.45(d,J=6.1Hz,2H),2.77(d,J=5.5Hz,2H),
3.87(br s,1H),5.22(br s,1H).
1.42(s,9H),1.46(s,9H),2.27(m,2H),
2.40−2.64(m,4H),
3.20(dd,J=4.3,13.5Hz,1H),
3.56−3.70(m,2H),3.76−3.91(m,2H),
4.16(m,1H),5.20(d,J=8.6Hz,1H).
1.32(s,9H),2.20−2.43(m,6H),
3.26−3.31(m,2H),3.61(m,1H),3.81(m,1H),
4.02(m,1H),6.73(d,J=8.6Hz,1H),
12.16(s,1H).
比較例1−1:5−アミノ−4,4−ジフルオロペンタン酸メチル塩酸塩の合成
2.35(m,2H),2.59(t,J=7.6Hz,2H),
3.49(t,J=15.3Hz,2H),3.68(s,3H).
前記実施例4で得られた化合物(1.93g)をジクロロメタン(20.0g)とH2O(4.0g)に溶かした溶液に、NaBr(0.8g)とTEMPO(11mg、1モル%)を加えた。この反応溶液に5%のNaOCl(11.5g)とNaHCO3(1.7g)をH2O(12.0g)に溶かした溶液を5℃以下の温度を保持しながら約2時間かけて滴加した。滴加完了後、反応溶液を30分間撹拌して層分離した。そのようにして得られた有機層に、上記比較例1−1で得られた化合物(1.6g)を加えた。室温で15分間撹拌後、NaBH(OAc)3(2.23g)を反応溶液に加えた。約19時間撹拌後、10%のNaHCO3水溶液(20.0g)と0.5Nの塩酸水溶液(20.0g)を反応溶液に滴加して層分離した。そのようにして得られた有機層を無水MgSO4で脱水して、実施例14と同じ表題化合物(2.0g、収率73%)を黄色固体として得た。前記から得られた表題化合物に対して、その鏡像異性体、すなわち、S体とR体をHPLC(高性能液体クロマトグラフィー)で測定した後、鏡像異性体(S体対R体)の過剰率(ee)を算出したところ、eeは80%であった。
Claims (20)
- 式(4)の化合物を式(5)の化合物と反応させることを特徴とする、式(2)の化合物を製造する方法:
(式中、R3、R4、R5及びR6は、独立して、水素、ハロゲン、又は置換若しくは非置換のC1−C4アルキルであり;
P1は、アミン保護基であり;
それぞれのP2及びP3は、独立して、ベンジル基、メチル基、エチル基、i−プロピル基又はt−ブチル基であり;
G1Oは、トリフレート、メシレート、トシレート、ベシレート及びノナフレートよりなる群より選ばれる離脱基である)。 - (a)式(4)の化合物と式(5)の化合物に塩基を加えて、カップリング反応を行う工程、
(b)酸を加え、環化反応を行って、式(2a)の化合物を得る工程、及び
(c)得られた式(2a)の化合物を加水分解して、式(2)の化合物を得る工程、
を含んでなる、請求項1に記載の方法。
(式中、R3、R4、R5、R6、P1及びP2は請求項1に定義された通りである。) - P2がt−ブチル基であり、そしてP3がメチル又はエチル基であることを特徴とする、請求項1又は2に記載の方法。
- R3及びR4が水素であり、そしてR5及びR6がフッ素であることを特徴とする、請求項1又は2に記載の方法。
- 工程(a)で、塩基としてC1〜C4トリアルキルアミンを用いることを特徴とする、請求項2に記載の方法。
- 工程(b)で、酸として酢酸を用いることを特徴とする、請求項2に記載の方法。
- P1がBocであり、そしてP2がt−ブチルである式(2a)の化合物の場合、当該工程(c)の加水分解を塩基条件下で行い、P1とP2の保護基中のP2のみ選択的に除去して、式(2)の化合物を提供することを特徴とする、請求項2に記載の方法。
- 塩基として水酸化ナトリウム水溶液を用いることを特徴とする、請求項7に記載の方法。
- (a)式(7)の化合物を還元して、1級アルコール化合物を得る工程;及び
(b)上で得られたアルコール化合物を式(5)の化合物のG1O部分に対応するG1化合物と反応させて、式(5)の化合物を得る工程、
を含んでなる方法によって式(5)の化合物を製造する、請求項1に記載の方法:
(式中、R3、R4、R5、R6及びP3は、上記請求項1に定義された通りであり;
P4はベンジル基、メチル基、エチル基、i−プロピル基又はt−ブチル基であり;
G 1 化合物は、トリフルオロメタンスルホン酸無水物(Tf 2 O)、トリフルオロメタンスルホニルクロリド(TfCl)、メタンスルホニルクロリド(MsCl)、トルエンスルホニルクロリド(TsCl)、ブロモベンゼンスルホニルクロリド(BsCl)、(CF 3 (CF 2 ) 3 SO 2 )F及び(CF 3 (CF 2 ) 3 SO 2 ) 2 Oよりなる群から選ばれる)。 - 工程(a)で、NaBH4を用いて還元することを特徴とする、請求項9に記載の方法。
- (a)式(8)の化合物のカルボン酸にP2基を導入し、エステル基に変換して、式(9)の化合物を得る工程、
(b)式(9)の化合物に存在するエステル基P5を選択的に還元して、式(10)の化合物を得る工程、
(c)式(10)の化合物にG2O離脱基を導入して、式(11)の化合物を得る工程、
(d)式(11)の化合物をアジド化合物と反応させて、式(12)の化合物を得る工程、及び
(e)式(12)の化合物に水素化反応を行って、式(4)の化合物を得る工程、
を含んでなる方法によって式(4)の化合物を製造する、請求項1に記載の方法:
(式中、P1及びP2は請求項1に定義された通りであり、
P5はメチル基、エチル基、i−プロピル基又はt−ブチル基であり、
G2Oは離脱基である)。 - P1がBocであり、P2がi−プロピル基又はt−ブチル基であり、そしてG2Oがトリフレート又はノナフレートであることを特徴とする、請求項11に記載の方法。
- (a)式(13)のカルボン酸化合物を活性化エステルに変換した後、2級アミン化合物と反応させて、式(14)のアミド化合物を得る工程、
(b)式(14)の化合物のアミド基を還元して、式(15)の3級アミン化合物を得る工程、及び
(c)式(15)の3級アミン化合物に脱ベンジル化反応を行って、式(4)の化合物を得る工程、
を含んでなる方法によって式(4)の化合物を製造する、請求項1に記載の方法:
(式中、P1及びP2は請求項1に定義された通りであり、
P6はモノベンジルアミン、ジベンジルアミン、モノアリルアミン又はジアリルアミンである)。 - (a)式(13)のカルボン酸化合物を活性化エステルに変換した後、窒素源化合物と反応させて、式(16)のアミド化合物を得る工程、
(b)式(16)の化合物のアミド基を還元して、式(17)のニトリル化合物を得る工程、及び
(c)式(17)のニトリル化合物に水素化反応を行って、式(4)の化合物を得る工程、
を含んでなる方法によって式(4)の化合物を製造する、請求項1に記載の方法:
(式中、P1及びP2は請求項1に定義された通りである)。 - P1がBocであり、P2がi−プロピル又はt−ブチルであることを特徴とする、請求項14に記載の方法。
- 工程(a)で、活性化試薬としてクロロホルメート又はBoc2Oを用いることを特徴とする、請求項14に記載の方法。
- 工程(a)で用いられる窒素源化合物がアンモニアガス又はアンモニウム塩であることを特徴とする、請求項14に記載の方法。
- 工程(b)で、トリフロオロメタンスルホン酸無水物とEt3N、又は塩化シアヌルとDMFを用いて還元することを特徴とする、請求項14に記載の方法。
- 工程(c)で、パラジウム、塩化ニッケル(I)、酸化白金(IV)及び水酸化パラジウムから選ばれる金属を用いて水素化反応を行うことを特徴とする、請求項14に記載の方法。
- 工程(c)で、水酸化パラジウム金属、酢酸及び水素を用いて水素化反応を行うことを特徴とする、請求項14に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100086619 | 2010-09-03 | ||
| KR10-2010-0086619 | 2010-09-03 | ||
| PCT/KR2011/006260 WO2012030106A2 (en) | 2010-09-03 | 2011-08-25 | Production method of intermediate compound for synthesizing medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013543484A JP2013543484A (ja) | 2013-12-05 |
| JP5705985B2 true JP5705985B2 (ja) | 2015-04-22 |
Family
ID=45023417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527003A Active JP5705985B2 (ja) | 2010-09-03 | 2011-08-25 | 医薬品合成用中間体化合物の製造方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8741927B2 (ja) |
| EP (1) | EP2611776B1 (ja) |
| JP (1) | JP5705985B2 (ja) |
| KR (1) | KR101378984B1 (ja) |
| CN (1) | CN103080088B (ja) |
| AP (1) | AP3270A (ja) |
| AR (1) | AR082881A1 (ja) |
| AU (1) | AU2011296767B2 (ja) |
| BR (1) | BR112013004988B1 (ja) |
| CA (1) | CA2810393C (ja) |
| CL (1) | CL2013000589A1 (ja) |
| CO (1) | CO6700826A2 (ja) |
| DK (1) | DK2611776T3 (ja) |
| EA (1) | EA022500B1 (ja) |
| EC (1) | ECSP13012471A (ja) |
| ES (1) | ES2607089T3 (ja) |
| HU (1) | HUE032484T2 (ja) |
| IL (1) | IL224954B (ja) |
| MA (1) | MA34490B1 (ja) |
| MX (1) | MX2013002277A (ja) |
| MY (1) | MY157423A (ja) |
| NZ (1) | NZ607694A (ja) |
| PE (1) | PE20131128A1 (ja) |
| PH (1) | PH12013500343A1 (ja) |
| PL (1) | PL2611776T3 (ja) |
| PT (1) | PT2611776T (ja) |
| SG (1) | SG188329A1 (ja) |
| SI (1) | SI2611776T1 (ja) |
| TW (1) | TWI438188B (ja) |
| UA (1) | UA107721C2 (ja) |
| UY (1) | UY33589A (ja) |
| WO (1) | WO2012030106A2 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2995612A1 (en) * | 2014-09-12 | 2016-03-16 | Université de Strasbourg | Novel non-natural amino acids, their process of preparation and uses thereof |
| KR102068754B1 (ko) * | 2017-04-20 | 2020-01-21 | 주식회사 엘지화학 | 의약품 합성용 중간체 화합물의 제조 방법 |
| PE20201169A1 (es) * | 2017-09-28 | 2020-10-28 | Lg Chemical Ltd | Metodo de produccion de un compuesto intermedio para sintetizar un medicamento |
| MX2020003543A (es) * | 2017-09-28 | 2020-07-29 | Lg Chemical Ltd | Metodo de produccion de un compuesto intermediario para sintetizar un medicamento. |
| CN111247127B (zh) * | 2017-11-16 | 2024-02-06 | 株式会社Lg化学 | 用于合成药物的中间体化合物的生产方法 |
| WO2019098551A1 (ko) * | 2017-11-16 | 2019-05-23 | 주식회사 엘지화학 | 의약품 합성용 중간체 화합물의 제조 방법 |
| CN113861061A (zh) * | 2021-10-25 | 2021-12-31 | 成都市科隆化学品有限公司 | 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法 |
| KR20250155700A (ko) | 2024-04-24 | 2025-10-31 | 주식회사 다산제약 | 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456768A (en) * | 1980-10-08 | 1984-06-26 | The University Of Chicago | Chemical synthesis |
| US5556982A (en) * | 1985-01-14 | 1996-09-17 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| DE3705272A1 (de) | 1987-02-19 | 1988-09-01 | Basf Ag | Verfahren zur reduktion von mono- und dicarbonsaeuren |
| US5417023A (en) * | 1993-12-27 | 1995-05-23 | Mandish; Theodore O. | Building panel apparatus and method |
| HK1049334B (en) * | 2000-03-17 | 2004-07-16 | Bristol-Myers Squibb Pharma Company | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| TWI357902B (en) * | 2005-04-01 | 2012-02-11 | Lg Life Science Ltd | Dipeptidyl peptidase-iv inhibiting compounds, meth |
| AU2007284161A1 (en) | 2006-08-09 | 2008-02-21 | Smithkline Beecham Corporation | Pyrrolidinone anilines as progesterone receptor modulators |
| KR20080071476A (ko) * | 2007-01-30 | 2008-08-04 | 주식회사 엘지생명과학 | 신규한 디펩티딜 펩티데이즈 iv(dpp-iv) 저해제 |
| UA103181C2 (ru) * | 2007-12-21 | 2013-09-25 | Ел Джи Лайф Сайєнсіз, Лтд. | Соединения, которые ингибируют дипептидилпептидазу-iv и фармацевтическая композиция, которая содержит их как активный агент |
-
2011
- 2011-08-25 MY MYPI2013000673A patent/MY157423A/en unknown
- 2011-08-25 AU AU2011296767A patent/AU2011296767B2/en active Active
- 2011-08-25 MX MX2013002277A patent/MX2013002277A/es active IP Right Grant
- 2011-08-25 EA EA201390336A patent/EA022500B1/ru unknown
- 2011-08-25 JP JP2013527003A patent/JP5705985B2/ja active Active
- 2011-08-25 ES ES11822081.3T patent/ES2607089T3/es active Active
- 2011-08-25 UA UAA201302600A patent/UA107721C2/ru unknown
- 2011-08-25 US US13/820,197 patent/US8741927B2/en active Active
- 2011-08-25 PL PL11822081T patent/PL2611776T3/pl unknown
- 2011-08-25 PH PH1/2013/500343A patent/PH12013500343A1/en unknown
- 2011-08-25 CN CN201180041893.9A patent/CN103080088B/zh active Active
- 2011-08-25 AP AP2013006763A patent/AP3270A/xx active
- 2011-08-25 CA CA2810393A patent/CA2810393C/en active Active
- 2011-08-25 SG SG2013014931A patent/SG188329A1/en unknown
- 2011-08-25 HU HUE11822081A patent/HUE032484T2/en unknown
- 2011-08-25 NZ NZ607694A patent/NZ607694A/en unknown
- 2011-08-25 PT PT118220813T patent/PT2611776T/pt unknown
- 2011-08-25 BR BR112013004988-0A patent/BR112013004988B1/pt active IP Right Grant
- 2011-08-25 WO PCT/KR2011/006260 patent/WO2012030106A2/en not_active Ceased
- 2011-08-25 PE PE2013000351A patent/PE20131128A1/es active IP Right Grant
- 2011-08-25 SI SI201131045A patent/SI2611776T1/sl unknown
- 2011-08-25 DK DK11822081.3T patent/DK2611776T3/en active
- 2011-08-25 EP EP11822081.3A patent/EP2611776B1/en active Active
- 2011-08-25 MA MA35699A patent/MA34490B1/fr unknown
- 2011-09-02 AR ARP110103214A patent/AR082881A1/es active IP Right Grant
- 2011-09-02 UY UY0001033589A patent/UY33589A/es unknown
- 2011-09-02 KR KR1020110089110A patent/KR101378984B1/ko active Active
- 2011-09-02 TW TW100131640A patent/TWI438188B/zh active
-
2013
- 2013-02-27 IL IL224954A patent/IL224954B/en active IP Right Grant
- 2013-03-01 EC ECSP13012471 patent/ECSP13012471A/es unknown
- 2013-03-01 CL CL2013000589A patent/CL2013000589A1/es unknown
- 2013-03-01 CO CO13042032A patent/CO6700826A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5705985B2 (ja) | 医薬品合成用中間体化合物の製造方法 | |
| JP4052523B2 (ja) | ピロロ[2,3−d]ピリミジン誘導体、その中間体及び合成 | |
| JP2023002679A (ja) | チトクロームp450モノオキシゲナーゼの阻害剤およびそれに関わる中間体 | |
| WO2009064476A1 (en) | Preparation of sitagliptin intermediate | |
| WO2014102826A1 (en) | The present invention relates to process for the preparation of tofacitinib and intermediates thereof. | |
| EP3337789A1 (en) | Process for preparation of vortioxetine hydrobromide | |
| JP5548129B2 (ja) | 不斉有機触媒 | |
| JP2010090031A (ja) | 二環性プロリン化合物の製造方法 | |
| CN108727224B (zh) | 药物合成用中间体的制备方法 | |
| KR100743617B1 (ko) | 고광학순도를 갖는 키랄 3-히드록시 피롤리딘 및 그유도체를 제조하는 방법 | |
| HK1184787B (en) | Production method of intermediate compound for synthesizing medicament | |
| JPWO2004099136A1 (ja) | ピロリジン誘導体の製造方法 | |
| OA16339A (en) | Production method of intermediate compound for synthesizing medicament. | |
| EP1926709A1 (en) | Process for the preparation of chiral 3-hydroxy pyrrolidine compound and derivatives thereof having high optical purity | |
| JP4187822B2 (ja) | 光学活性4−ヒドロキシ−2−ピロリドンの製造方法 | |
| AU2250001A (en) | Process and intermediates to a tetrahydro-(1,8)-naphthyridine | |
| JP2703048B2 (ja) | プロリン誘導体の製法 | |
| KR100896087B1 (ko) | 광학적으로 순수한 2-메틸피롤리딘 및 그 염의 제조방법 | |
| KR100574343B1 (ko) | 입체선택적 4-하이드록시-2-피페리디논의 제조방법 | |
| JP4799756B2 (ja) | N−置換−1−アミノ−5−ハロ−2−ペンタノン誘導体又はその塩及びそれらの製造法 | |
| JPWO2005066124A1 (ja) | ピロリジン誘導体の製造法 | |
| JP2009508961A (ja) | アミノ酸誘導体の製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140812 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141024 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150225 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5705985 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |